Title: OLIGOMERIC KETONE COMPOUNDS

Abstract: A novel keto8enic compound is provided having general: Formula R(OCH(CH₃)CH₂C(O))ₙ-O-A wherein n is an integer of 3 to 10, A is the residue of a 3-keto alkan-1-01 and R is selected from the group consisting of H, C1-C6 alkyl and acetooacetyl. Preferred compounds are those wherein A is a residue of 4-hydroxy-2-butano. A particularly preferred compound is a 4-hydroxy-2-butano ester of an R-3-hydroxybutyrate oligomer having general: Formula H(OCH(CH₃)CH₂C(O))ₙ-O-CH₂-CH₂-(CO)-CH₂ Nutraceutical and pharmaceutical compositions are provided for use in treating one or more of acute trauma, hemorrhagic shock, neurodegeneration, diabetes, and epilepsy, stroke, head trauma, myocardial infarction, congestive heart failure, pulmonary failure, kidney failure, obesity depression, pain and impaired cognition.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC: C07C 69/66(2006.01); A61K 31/215(2006.01); A61K 31/00(2006.01)

USPC: 560/174, 185; 514/529; 424/439

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 560/174, 185; 514/529; 424/439

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 6,207,856 B1 (VEECH) 27 March 2001 (27.03.2001), entire document.</td>
<td>1-5 and 8-11</td>
</tr>
<tr>
<td>---</td>
<td></td>
<td>12-16</td>
</tr>
<tr>
<td>A</td>
<td></td>
<td>1-5, 8-12</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

- Special categories of cited documents:
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier application or patent published on or after the international filing date
  - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed
  - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - "&" document member of the same patent family

Date of the actual completion of the international search
11 October 2006 (11.10.2006)

Date of mailing of the international search report
09 NOV 2006

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (571) 273-3201

Authorized officer
Sikar A. Witherspoon
Telephone No. (571) 272-1600

Form PCT/ISA/210 (second sheet) (April 2005)
INTERNATIONAL SEARCH REPORT

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. □ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. □ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 6 and 7
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.

3. □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

□ The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.

□ The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.

□ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(2)) (April 2005)
Continuation of B. FIELDS SEARCHED Item 3:
REGISTRY, HCAPLUS, HCAOLD, CHEMCAT, WEST
search terms: oligomeric ketone, hydroxybutyrate, hydroxybutyric acid, ketoalcohol, ketalkanol, lipase, pharmaceutical, nutraceutical